Heliolitid corals and their competitors: a case study from the Wellin patch reefs, Middle Devonian, Belgium

peer reviewedWellin patch reefs are small Upper Eifelian build?ups within the fine?grained argillaceous limestone of the Hanonet Formation. Whereas the reefs themselves are not well exposed, their fossil assemblage is accessible in the hills near the town of Wellin, approximately 40xA0km SE of Dinant in Belgium. It is especially rich in massive stromatoporoids, heliolitids and other tabulate corals. They exhibit predominantly domical and bulbous morphologies. This paper focuses primarily on the palaeoautoecology of the heliolitid corals and their relationships with other organisms. Cases of mutual overgrowth between heliolitids, other corals and stromatoporids suggest a high degree of competition for space on the reefs, possibly related to the scarcity of hard substrates. Coral and stromatoporoid growth forms, as well as the prevalence of micritic matrix, point to a relatively low energy environment. However, abundant growth interruption surfaces, sediment intercalations and rejuvenations of corals suggest episodically increased hydrodynamic regime and sediment supply. It is inferred that the patch reefs developed in a relatively shallow environment, where the reefal assemblage was regularly affected by storms. Heliolitids exhibited high sediment tolerance and relied on passive sediment removal for survival. They also could regenerate effectively and commonly overgrew their epibionts, after the colony’s growth was hampered by the sediment. This is recorded in extremely abundant growth interruption surfaces, which allow the analysis of the impact of sediment influxes on the heliolitid corals. ? 2021 Lethaia Foundation. Published by John Wiley & Sons Lt

The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL

Objective: To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab

Health-related quality of life in multiple sclerosis: Effects of natalizumab

Objective: To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods: HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-la (IFN-\u3b2-1a) plus natalizumab 300mg (n = 589), or IFN-\u3b2-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated. Results: Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab. Interpretation: HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. \ua9 2007 American Neurological Association. Published by Wiley-Liss, Inc